Psoriasis, from Pathogenesis to Therapeutic Strategies: IL-21 as a Novel Potential Therapeutic Target

Author(s): Elisabetta Botti, Giulia Spallone, Roberta Caruso, Giovanni Monteleone, Sergio Chimenti, Antonio Costanzo

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 10 , 2012

Become EABM
Become Reviewer
Call for Editor


Psoriasis is a common (1-3% of the population worldwide), multifactorial, immune-mediated chronic skin disease. In psoriasis pathogenesis an over-reaction of local innate immune response initiates inflammation with subsequent involvement of adaptive immune response leading to the production of a panel of cytokines, chemokines and growth factors leading to epidermal hyperplasia. Recently, IL-21 has been involved in this process as this cytokine is overexpressed in psoriatic skin and can cause epidermal hyperplasia and inflammation when injected intradermally into mice. Moreover blockade of IL-21 with a human antibody against IL-21 reduces the epidermal thickness and the expression of Th1 and Th17 genes in the well-characterized model of human psoriasis-xenograft mouse. Therefore, the inhibition of this cytokine may be therapeutically effective in the treatment of psoriasis. Here we will review recent data on psoriasis pathogenesis focusing on the role of IL-21 as novel therapeutic target.

Keywords: IL-21, Psoriasis, Th17, biologics, fusion proteins, therapy, immune-mediated chronic, cytokines, chemokines, epidermal hyperplasia, human antibody, cytokine, novel therapeutic target, molecular mechanisms, immunosuppressive drugs.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 23 July, 2012
Page: [1861 - 1867]
Pages: 7
DOI: 10.2174/138920112802273281
Price: $65

Article Metrics

PDF: 21